Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis

Transcriptional Complex Formation of c-Fos, STAT3, and Hepatocyte NF-1  Is Essential for Cytokine-Driven C-Reactive Protein Gene Expression

(2014) T. Nishikawa et al.   JOURNAL OF IMMUNOLOGY

Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab

(2014) Shoko Nakajima et al.   Modern Rheumatology

Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis

(2014) Tomoyuki Imagawa et al.   Modern Rheumatology

Radiographic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following tocilizumab treatment

(2011) Y. Inaba et al.   ANNALS OF THE RHEUMATIC DISEASES

Therapeutic Targeting of the Interleukin-6 Receptor

(2011) Toshio Tanaka et al.   Annual Review of Pharmacology and Toxicology

The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis

(2011) Yu-Tsan Lin et al.   AUTOIMMUNITY REVIEWS

Inhibitory effects of IL-6 on IGF-1 activity in skeletal myoblasts could be mediated by the activation of SOCS-3

(2011) Nasser Al-Shanti et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Juvenile idiopathic arthritis

(2011) Berent Prakken et al.   LANCET

Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions

(2011) Elizabeth D. Mellins et al.   Nature Reviews Rheumatology

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data

(2011) F De Benedetti et al.   Pediatric Rheumatology

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

(2011) Timothy Beukelman et al.   ARTHRITIS CARE & RESEARCH

Hepcidin and Disorders of Iron Metabolism

(2010) Tomas Ganz et al.   Annual Review of Medicine

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series

(2010) Peter A. Nigrovic et al.   ARTHRITIS AND RHEUMATISM

Macrophage activation syndrome: advances towards understanding pathogenesis

(2010) Alexei A Grom et al.   CURRENT OPINION IN RHEUMATOLOGY

IL-6: Regulator of Treg/Th17 balance

(2010) Akihiro Kimura et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis

(2010) Shumpei Yokota et al.   Expert Review of Clinical Immunology

Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation

(2010) Shigeru Kotake et al.   JOURNAL OF BONE AND MINERAL RESEARCH

IL-17 and Th17 Cells

(2009) Thomas Korn et al.   Annual Review of Immunology

Interleukin-6 inhibits early differentiation of ATDC5 chondrogenic progenitor cells

(2009) Shoko Nakajima et al.   CYTOKINE

Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis

(2009) K. Nistala et al.   RHEUMATOLOGY

The pattern of response to anti–interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

(2008) Marco Gattorno et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

(2008) Shumpei Yokota et al.   LANCET

2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)

(2008) S Yokota et al.   Pediatric Rheumatology